Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update
Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering
Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform
Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update
Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc
Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer
Xenetic Biosciences Provides Update on Annual Meeting of Stockholders
Xenetic Biosciences Announces Dismissal of Annual Meeting of Stockholders
Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update
